Immune-Checkpoint Inhibitors Protect Bone by Promoting Osteogenesis

KREMS, Austria - May 22, 2024 - PRLog -- Immune checkpoint inhibitors (ICIs), widely employed anticancer agents, have been found to impact bone turnover, potentially conferring a protective effect on bone through the promotion of osteogenesis. These surprising findings stem from a recent study conducted at the Karl Landsteiner University of Health Sciences (KL Krems), Austria, the results of which have been published in the Journal for Immuno Therapy for Cancer. The study was a comprehensive in vivo, in vitro and ex vivo analysis on the effects of PD1- or PD-L1 inhibitors on bone turnover. These results diverge from previous research indicating ICIs' potential contribution to skeletal morbidity, a significant concern for patients with advanced cancer.

Antitumor agents may have detrimental impact on the bone health of cancer patients, leading to skeletal morbidity. This elevates the risk of fractures and undermines quality of life. Thus, safeguarding bone health alongside enhancing outcomes are important treatment goals. While immune checkpoint inhibitors (ICIs), in particular PD1- and PD-L1 inhibitors, are considered standard of care in many cancers, their effect on bone health is still under debate with studies indicating their potential contribution to skeletal morbidity, a significant concern for patients with advanced cancer. In a comprehensive in-vivo, in-vitro and ex-vivo analysis, Dr. Sonia Vallet and her collaborators demonstrated a favorable effect of ICIs on bone turnover.

Original Publication: Favorable Impact of PD1/PD-L1 Antagonists on Bone Remodeling: An Exploratory Prospective Clinical Study and ex-vivo Validation. T. Gassner, C. Chittilappilly, T. Pirich, B. Neuditschko, K. Hackner, J. Lind, O. Aksoy, U. Graichen, S. Klee, F. Herzog, C. Wiesner, P. Errhalt, M. Pecherstorfer, K. Podar & S. Vallet. Journal of Immunotherapy of Cancer May 2024 - Vol 12 - 5. https://doi.org/10.1136/jitc-2023-008669

https://kris.kl.ac.at/en/publications/favorable-impact-of-pd1pd-l1-antagonists-on-bone-remodeling-an-ex

Scientific Contact

OA PD Dr. Sonia Vallet

Department of Internal Medicine 2

University Hospital Krems

and Division of Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences

Mitterweg 10

3500 Krems an der Donau

T +43 2732 9004 12355

E sonia.vallet@krems.lknoe.at

W (https://kris.kl.ac.at/en/publications/favorable-impact-of-pd1pd-l1-antagonists-on-bone-remodeling-an-ex) http://www.krems.lknoe.at

Copy Editing & Distribution

PR&D – Public Relations for Research & Education

Dr. Barbara Bauder

Kollersteig 68

3400 Klosterneuburg / Austria

M +43 664 1576 350

E  bauder@prd.at

L https://www.linkedin.com/company/prd-public-relations-für-forschung-bildung (https://www.linkedin.com/company/prd-public-relations-f%C3%BCr-forschung-bildung)

W (http://www.krems.lknoe.at/) https://www.prd.at/